Profile: Biopharmx Corp (BPMX.N)
22 Jul 2019
BioPharmX Corporation, incorporated on April 24, 2014, is a specialty pharmaceutical company. The Company is focused on utilizing its drug delivery technologies to develop and commercialize prescription and over-the-counter (OTC) products that address markets in women's health and dermatology. The Company's platform technologies include delivery mechanisms for molecular iodine (I2) and antibiotics. The Company focuses on developing products that treat health or age-related conditions, including which are not being addressed or treated or, which are treated with drug therapies or drug delivery approaches that are sub-optimal. The Company's portfolio of product candidates includes two clinical stage product candidates: BPX01, which is a topical antibiotic for the treatment of acne based on a formulation of minocycline, and BPX03, which is a molecular iodine (I2) tablet for the treatment of benign breast pain associated with fibrocystic breast condition (FBC) and cyclic mastalgia. The molecular iodine project includes an OTC dietary supplement version or VI2OLET, for the alleviation of symptoms of FBC, as well as a prescription drug version for the treatment of moderate to severe, periodic breast pain associated with FBC and cyclic mastalgia.
The Company's VI2OLET is an OTC molecular iodine dietary supplement that addresses cyclic breast discomfort and is clinically demonstrated to alleviate the symptoms associated with FBC, including tenderness, aches and swelling. Women suffering from menstrual-related breast discomfort are recommended to take 1 to 2 tablets per day on an empty stomach for approximately 60 days to realize initial symptom relief.
The Company's BPX03 is a prescription drug version of its molecular iodine tablet for the treatment of moderate to severe, periodic breast pain associated with FBC and cyclic mastalgia. The Company focuses on the process of conducting a clinical study (using VI2OLET) under Health Canada and institutional review board (IRB).
The Company is developing BPX01, which is a hydrophilic, topical antibiotic for the treatment of acne. BPX01 is a formulation and utilizes a transepidermal delivery mechanism for minocycline that has the potential to kill Propionibacterium acnes bacteria without the systemic side effects of orally-administered antibiotics. BPX01 contains an active pharmaceutical ingredient that is expected to possess anti-inflammatory properties, which reduce swelling and redness. BPX01 is in Phase II clinical trials.
The Company is developing BPX02, which is an injectable utilizing biologic materials for aesthetic dermatology applications. BPX02 is under internal development with preclinical testing.
115 Nicholson Ln
SAN JOSE CA 95134-1359